Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • The Bureau of Indian Standards, BIS has classified microbeads as unsafe for use in cosmetic products, the government reported to the National Green Court. The petition was made in response to a plea filed by Ashwini Kumar, a Delhi lawyer, who sought a total ban on the use of microspheres in the manufacture, import and sale of various cosmetics or personal care products.

    The Ministry of Health and Family Welfare told a bank headed by Judge Jawad Rahim that BIS published a document on May 16 Classification of raw materials and cosmetic supplements, Part 2 List of raw materials generally not recognized as safe for its Use in cosmetics By incorporating non biodegradable polymer microbeads into the prohibited list.

    It is stated that this draft notification was not issued by the Ministry of Health but was issued by a different department which is BIS. After this information, the affidavit containing the draft notification was submitted to the approval of the General Controller Of Drugs of India, an affidavit by the Health Ministry said.

    Kumar has claimed that microspheres escape filtration and wastewater treatment processes and end up in rivers, which ultimately lead to the ocean where they contribute to the huge amount of plastic soup in the environment. Attorney Sumeer Sodhi, who appears before the petitioner, said that the voluntary step of the Ministry of Health and Family Welfare to ban cosmetics microspheres would be a monumental step to reduce the water pollution.


    The voluntary step of the Ministry of Health would be a monumental step towards reducing water pollution from plastic (marine and other) and would put India on the list of one of the few countries that have taken a step In this direction. The same has happened of course in promoting the cause raised by the applicant, he  said.

    The NGT had previously directed the Center to test cosmetic products containing microspheres after a request to prohibit their use in soil that are extremely hazardous to aquatic life and the environment. He said it is the governments duty to ensure that no dangerous product is allowed to be manufactured or sold to the public and directed to the Central Drug Organization to analyze the products in a laboratory and report in four weeks.


    << Back to Pharma News

    Subscribe to PharmaTutor News Alerts by Email

  • The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

  • The U.S. Food and Drug Administration expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis.

    [adsense:336x280:8701650588]

  • Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented entitled “Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response” (Poster No. 3001130) at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry in San Diego. The poster can be found on the Scientific Presentations page on Tonix’s website. A moderator is a characteristic of study participants that is associated with a treatment response.

  • Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug–target binding in a physiological environment and at clinically-relevant concentrations. They revealed differences between the three drugs in the size and structure of the complexes formed, which may explain differences in the drugs’ clinical efficacy. This technique could help optimize future drug design.

  • No Child should die in the country from Vaccine Preventable Diseases. We stand committed to reducing child deaths: Shri J P Nadda

    “No child should die in the country from Vaccine Preventable Diseases” is the Goal & Commitment of our government. We stand committed to reducing child deaths and providing a healthier future to our children.” Shri J P Nadda, Union Minister for Health and Family Welfare stated this as he announced the introduction of pneumococcal conjugate vaccine (PCV) in the Universal Immunization Programme (UIP) of the country in a function at Mandi, today. Terming this as an historic moment and an exemplary step in India’s immunization programme, the Union Health Minister added that the Government is committed to reducing morbidity and mortality in children. Strengthening routine immunization is an essential investment in India’s children and will ensure a healthy future of the country, he noted.

Subscribe to Pharma News